Life Sciences Tools and Services
Company Overview of Myriad RBM, Inc.
Myriad RBM, Inc., a multiplexed immunoassay testing laboratory, provides multi-analyte profile (MAP) technology platform based protein biomarker products and services for research, drug, and diagnostic development projects. Its products and services include HumanMAP services that assist investigators in the discovery, validation, and clinical use of biomarker patterns in biological samples, such as serum or plasma; and RodentMAP services that provide quantitative measurement of various biomarkers to enable new pattern discovery, as well as sensitive safety and efficacy assessments. The company’s products and services also comprise single molecule array technology based Ultrasensitive Immunoa...
3300 Duval Road
Austin, TX 78759
Founded in 2002
Key Executives for Myriad RBM, Inc.
Chief Scientific Officer and Senior Vice President
Chief Medical Officer and Senior Vice President
Vice President of IS & Technology
Managing Director of Communications
Compensation as of Fiscal Year 2016.
Myriad RBM, Inc. Key Developments
Myriad RBM DiscoveryMAP(R) Technology Identifies Novel Biomarkers That May Predict Increased Risk of Cardiovascular Events in Patients with Diabetes
Nov 16 15
Myriad RBM announced that its DiscoveryMAP® platform successfully identified combinations of 15 protein biomarkers associated with cardiovascular (CV) events or death in people with pre-diabetes or early type 2 diabetes, according to a study published by the journal Circulation. DiscoveryMAP is a comprehensive, quantitative, immunoassay service product that measures more than 300 human proteins. It is the culmination of 15 years of assay development for cytokines, chemokines, metabolic markers, hormones, growth factors, tissue remodeling proteins, angiogenesis markers, acute phase reactants, cancer markers, kidney damage markers, CNS biomarkers and other important circulating proteins.
CDC Plans Sole Source with Rules-Based Medicine for Proteome Evaluation
Jul 19 15
The U.S. Health and Human Services Department's Centers for Disease Control and Prevention, Atlanta, said it intends to enter into a sole source contract (2015-63697SG) with Rules-Based Medicine Inc., Austin, Texas, for the evaluation of proteomes.
Myriad RBM Launches New Immunoassay Services Based on the Ultrasensitive Simoa(TM) Platform
Mar 5 15
Myriad RBM announced the launch of immunoassay services based on the ultrasensitive Simoa™ (single molecule array) platform developed by Quanterix. The Simoa platform enables the accurate measurement of protein biomarkers that were previously difficult or even impossible to detect in blood samples. Initially, Myriad RBM will offer Simoa assay services for the study of inflammatory and autoimmune diseases. The company has manufactured and validated Simoa-based quantitative immunoassays for interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha) that are available from its CLIA-certified laboratory in Austin, Texas. Each assay includes carefully designed calibrators and controls to provide multiple measurements of quality, precision and accuracy. Myriad RBM plans to add more Simoa-based immunoassays throughout the year.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|